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Objective. To determine the impact of an integrative medicine clinical pathways (CPs) on the length of in-hospital stay and on
outcomes for patients with acute myocardial infarction (AMI). Methods. A multicenter nonrandomized controlled trial enrolling
197 consecutive patients with AMI at eight urban TCM hospitals was conducted between 1 January 2010 and 31 October 2010.
These patients were enrolled in the interventional group after the CPs had been implemented. The control group included 405
patients with AMI from eight hospitals; these patients were treated between 1 January 2008 and 31 December 2009, before the
CPs were implemented. Outcome measures were the length of hospital stay costs of medical care, and major cardiovascular events
(MACEs) during hospitalization. Results. Compared with the control group, the patients in intervention group had a shorter
length of hospital stay (9.2 ± 4.2 days versus 12.7 ± 8.6 days, P < 0.05), and reduced healthcare costs in hospital (46365.7 ± 18266.9
versus 52866.0 ± 35404.4, P < 0.05). There were statistically significant diﬀerences in MACE between the two groups during the
hospitalization period (2.5% versus 6.9%, P = 0.03). Conclusion. These data suggest that the development and implementation of
the clinical pathways based in Integrative Medicine could further improve quality of care and outcome for patients with AMI.

1. Introduction
Acute myocardial infarction (AMI) is a serious cardiovascular disease and is a leading cause of death worldwide. In
recent years, the AMI incidence and mortality has decreased
significantly in America because early reperfusion and drug

treatment has been standardized [1]. However, it is estimated
that with further economic development, aging of the
population, and changes in diet and physical activity in
China, the absolute number of AMI events and deaths will
increase dramatically in the next two decades [2]. There is
also a discrepancy between guideline recommendations and
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the current AMI management in most Chinese hospitals
[3]. Therefore, strong evidence-based initiatives to improve
patient management will be critical to address this challenge.
TCM has been practiced for thousands of years, and it has
made great contributions to peoples’ health and wellbeing.
Epidemiological data has suggested that Chinese herbal
preparations may be beneficial in reducing the mortality
from AMI, and TCM treatment was shown to help improve
the quality of life for AMI patients [4]. TCM hospitals
have the ability to perform reperfusion and to use drugs
appropriately, and they are also making progress in their
eﬀort to follow the Clinical Guidelines. However, there
are still situations that arise when using TCM to treat
patients with AMI, including a lack of standardized TCM
syndrome diagnosis, the need for syndrome diﬀerentiation
and treatment standardization, and clinical skills in reperfusion and standardized drug treatment, which require further
improvement [5].
Clinical pathways (CPs), also known as critical pathways,
are management plans that display goals for patients and
provide the sequence and timing of actions necessary to
achieve these goals with optimal eﬃciency. As competition
in the healthcare industry has increased, CPs have been
widely implemented as a method to reduce variation in care
and potentially improve healthcare quality. Cardiovascular
medicine in particular is an area in which CPs have been used
extensively [6]. The evidence-based Integrative Medicine
CPs, developed to improve the quality of healthcare, was
based on published guidelines and the best research evidence
from TCM and Western medicine [7]. Previous research
has suggested that CPs may help to reduce costs while
improving the quality of care for AMI patients [8]. However,
the eﬀectiveness of Integrative Medicine CPs on improving
AMI management is unclear.
In previous studies, we developed CPs based on standardized therapy for AMI Integrative Medicine. The standardized management included thrombolysis therapy, primary
percutaneous coronary intervention (PCI), antiplatelet and
anti-ischemic therapy, and TCM therapy (such as Astragalus
injection and compound Danshen dripping pills) to benefit
Qi and to activate blood. A small single-center trial suggested
that the CPs could reduce the length of the hospital stay
and in-hospital health care costs for patients with AMI who
underwent PCI [9]. The purpose of this study is to assess
further the influence of the Integrative Medicine CPs on care
quality and outcomes among AMI patients in TCM hospitals,
in a multicenter nonrandomized controlled trial.

Hospital of TCM) (Figure 1). This study (2008GL-35) was
approved by the Ethical Committee of Guangdong Provincial
Hospital of Chinese Medicine.

2. Methods

2.3. Intervention. The patients in the historical control group
received conventional management determined by a physician, which included Western medicine and nonstandardized
TCM therapy. The patients in the intervention group were
treated according to the standardized management plan as
determined by the CPs. The Western medical treatment
consisted of reperfusion therapy and aspirin, clopidogrel, low
molecular weight heparin (LMWH), β receptor blocker, and
angiotensin-converting enzyme inhibitors (or angiotensin II
receptor blocker), according to the 2007 updated guidelines

2.1. Study Design and Setting. This trial is a multicenter, nonrandomized retrospective study in eight hospitals (Guangdong Provincial Hospital of TCM; Shuguang Hospital of
Shanghai University of TCM; Yueyang Hospital of Integrated
Medicine of Shanghai University of TCM; Oriental Hospital
of Beijing University of TCM; Jiangsu Provincial Hospital
of TCM; 3rd Aﬃliated Hospital of Guangxi College of
TCM; Wuyi Hospital of TCM of Jiangmen city; Zhongshan

2.2. Study Patients. Inclusion criteria for this study included
patients with acute myocardial infarction (onset of chest pain
≤ 24 h) admitted to emergency, and ages ranging from 18 to
80 years old who agreed to emergency reperfusion therapy
(including intravenous thrombolysis or PCI). Exclusion
criteria included serious mechanical complications (such as
left ventricular free wall rupture, ventricular septal perforation, papillary muscles, and adjacent chordal rupture), concomitant diseases with aortic dissection, acute pulmonary
embolism, severe liver failure, renal failure, mental illness,
malignancy, hematopoietic tumor, nervous system primary
diseases, and pregnancy or lactation [10].
In our preliminary study, we found that Qi deficiency
and blood stasis were the main TCM syndromes for AMI
[11]. In order to implement the AMI CPs conveniently in all
hospitals, we considered Qi deficiency and blood stasis as the
basic syndrome occasionally accompanied with Phlegm, Yindeficiency or Yang-deficiency of a single TCM syndrome element. The diagnostic criteria of the Qi deficiency and blood
stasis were based on the TCM standard of coronary heart
disease, which was formulated by the Cardiovascular Society
of the National Association of Integrative Medicine [12].
Sample size was calculated using PEMS 3.1 for Windows
software (Sichuan University, Chengdu). The length of inhospital stay was considered to be one of the most important
factors in the calculation of sample size. The standard
deviation (SD) of the length of in-hospital stay for the
conventional treatment group was 6 days [13], and it was
considered clinically significant when the length of inhospital stay was reduced by 4 days. If α = 0.05, power = 0.90,
and β = 0.10, the estimated total sample size is 256 patients.
Taking into account a 15% dropout rate, the total sample size
is 294 patients.
In the study protocol, the planned sample size was
240 consecutive patients who were enrolled into the
intervention groups after pathway implementation. There
were 450 consecutive patients, admitted to the eight hospitals
between 1 January 2008 and 31 December 2009, prior to CP
implementation, who were included as a historical control
group. The Guangdong Provincial Hospital of TCM planned
to enroll 100 patients for the intervention group and 100
patients for the control group. Additionally, each of the other
7 hospitals planned to enroll 20 patients for the intervention
group and 50 patients for the control group.
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CPs based on integrative medicine for AMI

CP education and training

AMI, ≤24 h, age between 18 and 80 years

Intervention group

Length of hospital stay

Historical group

Medical expenditure

MACE

Optimization
of CPs

Variability management

Statistical analysis

Optimized management of integrative medicine for AMI

Figure 1: Evaluation of clinical pathways based on integrative medicine for AMI. CPs: clinical pathways, MACE: major adverse cardiac
events, AMI: acute myocardial infarction.

for the management of patients with ST-segment elevation
myocardial infarction (STEMI) [14].
For Qi deficiency and blood stasis, the standard TCM
technique performed in the intervention group was 30 mL
Astragalus injection (Astragalus, Zhengda Qingchunbao
pharmaceutical company) mixed with 250 mL 5% glucose,
which was infused intravenously once per day, and 10 particles of compound Danshen dripping pills (Salvia, Pseudoginseng, Borneol, Tasly Group) 3 times a day. Instead of
Astragalus injection, Gualou Xiebai Banxia Tang (Trichosanthes 15 g, Bulbus allii macrostemonis 20 g, Pinelliae 15 g)
was administered to patients with cold-phlegm syndrome,
Wen Dan Tang (Poria 15 g, Dried tangerine peel 10 g,
Pinellia 15 g, Caulis bambusae in taenia 15 g, Fructus aurantii
15 g) was administered for patients with heat-phlegm syndrome, 30 mL Shen Mai injection (Ginseng, Radix, Zhengda
Qingchunbao pharmaceutical company) mixed with 5% glucose injection infusion was administered for Yin-deficiency,
and 30 mL Shenfu (tuber, red ginseng, Sanjiu Ya pharmaceutical company) in 5% glucose intravenous infusion was
administered for Yang-deficiency. All the treatments were
administered for 1 week.
2.4. Outcome Measures. The primary outcome was the length
of the in-hospital stay. Discharge standard, for patients to be
discharged from the hospital with stable life signs (hemodynamic, electrocardiogram, and cardiac function) and
without the symptoms of myocardial ischemia, was determined according to “Clinical pathways of ST-segment elevation myocardial infarction” (2009 version) by the Medical Administration of the Ministry of Health [15]. The
secondary outcome was the major cardiovascular events

(MACE) and economic evaluation during the period of hospitalization. MACE is defined as death, nonfatal myocardial
reinfarction, stent thrombosis or target vessel revascularization. Total medical costs include treatment costs, operation
costs, drug costs, nursing costs, inspection fees, and bed
charges. All data were analyzed using SPSS 17.0 (IBM
Corporation, Armonk). Measurement data were presented
as mean ± ST. Count data were presented as the frequency
and constituent ratio, and analyzed using the chi-square test
or the exact test exact probability method. For measurement
data, two samples were compared using the Mann-Whitney
U test. The statistical tests used were two-sided tests, and
P < 0.05 was considered a statistically significant diﬀerence.

3. Results
Between 1 January 2010 and 31 October 2010, a total of
250 consecutive patients fulfilling the inclusion criteria were
initially evaluated as the intervention group, and 53 patients
were excluded because of severe mechanical complications
or severe liver failure and renal failure. A total of 450 patients
admitted to eight hospitals from 1 January 2008 to 31
December 2009 were screened for the historical control
group, and 45 patients were excluded because of severe
mechanical complications or concomitant diseases. As a
result, there were 197 patients enrolled into the intervention
group and 405 patients enrolled into the historical control
group.
3.1. Clinical Features in the Intervention and Historical Control
Groups. Of the 602 patients, 514 (85%) were admitted for
ST-segment elevation myocardial infarction (STEMI) and 71
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Table 1: Demographic and clinical features of patients.

Variable
Male gender
Age (yrs)
Hypertension
Diabetes
Hyperlipidemia
Previous coronary disease
Previous stroke
Current smoker
Family history of coronary disease
Clinical pattern
STEMI
NSTEMI
Cardiac function (Killips classification)
Level I
Level II
Level III
Level IV
Intravenous thrombolysis
Emergency PCI
Vascular lesions
Single
Two branch
Three branch
Stenosis < 50%
Stent implantation

Intervention group
(n = 197)
149 (75.6)
63.42 ± 11.87
109 (55.3)
37 (18.8)
58 (29.4)
14 (7.1)
20 (10.2)
106 (53.8)
16 (8.1)

Historical control group
(n = 405)
308 (76.0)
63.89 ± 13.20
214 (52.8)
55 (13.6)
65 (16.0)
22 (5.4)
34 (8.4)
196 (48.4)
65 (16.0)

176 (89.3)
21 (10.7)

338 (87.1)
50 (12.9)

99 (64.7)
31 (20.3)
10 (6.5)
13 (8.5)
8 (4.1)
189 (95.9)

275 (69.1)
70 (17.6)
23 (5.8)
30 (7.5)
27 (6.7)
378 (93.3)

64 (34.0)
56 (29.8)
65 (34.6)
3 (1.6)
1.19 ± 0.63

102 (30.0)
116 (34.1)
122 (35.9)
0 (0.0)
1.25 ± 0.90

χ 2 (Z)

P value

0.01
0.33
2.77
5.88
0.66
0.01
4.96
10.13

0.91
0.63
0.57
0.10
0.02
0.42
0.93
0.03
0.00

0.61

0.44

−0.96

0.34

1.64

0.20

−0.37

0.72

−0.11

0.92

−0.49

Values are given as number of patients (%) or mean ± SD.
STEMI: ST-segment elevation myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction.
PCI: percutaneous coronary intervention.

(15%) for non-ST-segment elevation myocardial infarction
(NSTEMI). There were 567 patients (94%) who underwent emergency PCI and 35 patients (6%) who received
intravenous thrombolysis. Patient characteristics were not
significantly diﬀerent between the intervention and control
groups. The only exceptions were a slightly increased number
of patients with a family history of coronary disease in
the control group compared to the intervention group, and
small increase in the number of patients in the intervention
group who had hyperlipidemia or who currently smoked,
compared to the control group (Table 1).
3.2. Drug Treatments. Comparing the main Western medicine drug treatments in both groups, there were no statistically
significantly diﬀerences among antiplatelet therapy (aspirin,
clopidogrel), beta receptor blockers, ACEI (or ARB), and
nitrate (P > 0.05). However, the prescribing frequency of
low molecular weight heparin (LMWH) and statins in the
intervention group was higher in the intervention group
than in control group (P < 0.05; Table 2).
The rate of Chinese medicine decoction use in the treatment group was significantly higher than in the control group (P < 0.01). There were also significant diﬀerences

Table 2: Western medicine prescribing frequency.
Variable
Antiplatelet
Low molecular
weight heparin
Statins
β receptor blockers
ACE inhibitors
(or ARB)
Nitrate esters
Antiarrhythmic
drugs

Intervention
group
(n = 197)
197 (100)

Historical
control group
(n = 405)
402 (99)

χ2

P

—

1.00∗

197 (100)

362 (89)

—

0.00∗

197 (100)
160 (81)

388 (96)
320 (79)

— 0.01∗
0.12 0.72

163 (82)

324 (80)

0.64 0.42

138 (70)

276 (68)

0.07 0.79

65 (33)

79 (20)

12.41 0.00

Values are given as number of patients (%).
∗ Using the exact probability method.
ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker.

among Compound Danshen dripping pills, Qi-benefitting
agents, and blood-activating agents (P < 0.05). The frequency of injections benefitting Qi was higher in the treatment group than in the control group, whereas injections
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Table 3: Chinese medicine prescribing frequency.
Intervention
Historical
group
control group
(n = 197)
(n = 405)

Variable
Chinese medicine
therapy
Compound Danshen
dripping pills
Qi-benefitting
intravenous agents
Blood-activating
intravenous agents♦

χ2

P

192 (97)

342 (84)

21.93 0.00

124 (63)

9 (7)

283.91 0.00

153 (78)

176 (43)

62.58 0.00

0 (0)

256 (63)

—

0.00∗

∗

Using the exact probability method.
intravenous agents are TCM injections whose indications
are to improve rehabilitation by benefitting Qi, and they include Astragalus
injection, Shen Mai injection, and Shenfu injection.
♦ Blood-activating intravenous agents are TCM injections whose indications
are to promote rehabilitation by promoting blood circulation and eliminating blood stasis, and they include Salvia injection, Saﬄower injection, and
Tetramethylpyrazine injection et al.
 Qi-benefitting

Table 4: Length of in-hospital stay.
Variable
Length of stay
(days)

x±s
M Z
P
Group
N
Intervention 197 9.2 ± 4.2 9
5.08 <0.001
Historical 405 12.7 ± 8.6 11

promoting blood circulation had a lower frequency in the
treatment group compared to the control group (Table 3).
3.3. The Average Length of In-Hospital Stay. The length of inhospital stay showed a skewed distribution in both groups,
and therefore a nonparametric test was used. The average
length of stay in the treatment group was 3.5 days less than
that of the control group, which was statistically significant
(P < 0.01; Table 4).
3.4. The Total In-Hospital Costs. The average hospitalization
costs had a skewed distribution in both groups, so a nonparametric test was used. In the intervention group, the average
total in-hospital charges were 48047.3 when it was adjusted
by the price index, which reduced to 4820.00 compared
with the control group. There were statistically significant
diﬀerences between intervention groups and control groups.
(P < 0.01; Table 5).
3.5. The Incidence of Major Cardiovascular Events (MACEs).
The major adverse events of death, nonfatal myocardial
reinfarction, stent thrombosis, and target vessel revascularization (TVR) occurred in 2.5% of patients (5 of 197) in
the interventional group and in 6.9% (28 of 405) of those in
the control group during hospitalization (P = 0.03; Table 6).
Three patients in the intervention group died due to cardiac
shock, and 22 patients died in the historical control group
due to cardiac shock (10 patients), severe heart failure (4
patients), ventricular fibrillation (5 patients), and multiple
organ dysfunction syndrome (3 patients). The majority of
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MACE incidents were death during hospitalization (1.5%
versus 5.4%, P = 0.03). There was no statistical diﬀerence in
nonfatal myocardial reinfarction, stent thrombosis, and TVR
between two groups (Table 6).

4. Discussion
The number of patients in China who develop and present
to hospitals with acute coronary syndrome will increase in
the near future. China’s fee-for-service payment system has
resulted in a rapid cost increase, ineﬃciencies, poor quality,
unaﬀordable health care, and an erosion of medical ethics
[16], and improvement of patient management, together
with health system reform, is urgently required. CPs are
management plans that specify goals for patients and provide
the sequence and timing of the actions necessary to achieve
these goals with optimal eﬃciency. Several areas for improving patient care using CPs have been identified, including
increasing the use of guideline-recommended medications,
reducing variation in care, targeting the use of cardiac
procedures, and reducing the length of the hospital stay [17].
Therefore, the Ministry of Health in China has encouraged
the implementation of CPs in cardiovascular disease to
control medical cost and to improve healthcare quality.
To standardize the AMI treatment-based integrative
medicine in TCM hospitals, we conducted this study and
evaluated the eﬃcacy of CPs in eight TCM hospitals. In
our study, there were more patients with hyperlipidemia
or who were current smokers, and fewer patients with a
family history of coronary disease in the intervention group
than in the historical control group. These data indicate
that, with diet and life-style changes in China, smoking and
hyperlipidemia have emerged as key risk factors leading to
AMI, especially for younger people.
4.1. Length of in-Hospital Stay. A previous epidemiological
study showed that the average length of hospital stay was
from 11.6 to 13.7 days in China for the patients with AMI
who were admitted to hospital within 12 h after onset of
chest pain [13]. Our trial indicated that the average length
of stay in the treatment group (after implementation of
CPs) was 3.5 days less than the control group (9.2 ± 4.2
days versus 12.7 ± 8.6 days, P < 0.01). The length of the
hospital stay after AMI depends on many factors, including
department policies, insurance coverage, age, and patients’
complications. However, the length of the hospital stay
depended more on the damaged myocardium duration of
recovery because there were few changes in the medical
policy and insurance coverage from 2008 to 2010, and there
are no statistical diﬀerences in age, cardiac function, and
other clinical characteristics between the interventional and
historical groups. In this study, we consistently followed the
hospital discharge standards, which ensured that the patients
would be discharged from hospitals in a stable condition.
Therefore, the reduction in the length of stay observed
in this study is attributed to the potential improvement
of healthcare quality and the decreased variation in care
conferred by the use of CPs.
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Table 5: In-hospital medical costs.

Variable
Total charges ()
Total charges adjusted by
price index ()

Group
Intervention
Control
Intervention
Control

N
197
405
197
405

Table 6: Individual and combined outcome measure of MACE
occurrence during hospitalization.
Variable
Intervention group
Death
3 (1.5)
Nonfatal MI
1 (0.5)
Stent thrombosis
1 (0.5)
TVR
0 (0)
Total
5 (2.5)

Historical group
22 (5.4)
1 (0.2)
2 (0.5)
3 (0.7)
28 (6.9)

P
0.03∗
0.55∗
1.0∗
0.56∗
0.03

x±s
48047.3 ± 18929.4
52866.0 ± 35404.4
46365.7 ± 18266.9
52866.0 ± 35404.4

M
44198.7
46157.8
42651.7
46157.8

Z

P

1.83

0.067

2.94

0.003

guideline. However, the prescribing frequency of β receptor
blockers and ACE inhibitors were not as high as expected in
the intervention group (81% and 82%, resp.). These findings
are not unique to TCM hospitals; data from CPACS has
consistently demonstrated that β receptor blockers and ACE
inhibitors are not being used as often or as long as they
should be, which reflects the physicians’ fears that these drugs
may lead to dynamitic deterioration in patients with cardiac
shock, acute heart failure, or low blood pressure [19].

∗

Using the exact probability method; MI: myocardial reinfarction; TVR:
target vessel revascularization.

4.2. Total In-Hospital Medical Costs. China’s current strategy
to improve payment for health services has made some
positive changes; however, the rapid increase in health expenditure and inappropriate treatment concerning individuals
and governments resulting from China’s fee-for-service
payment and a price schedule that overpays for drugs and
high-technological diagnostics tests has led providers to
overprescribe drugs and diagnostic tests [18]. Control of the
high out-of-pocket healthcare payments when patients have
inadequate insurance coverage in many parts of China is critical. Our study showed that, after the price index adjustment,
the total medical expenditure during hospitalization in the
intervention group was reduced compared to the historical
control group (46365.70 versus 52866.00, respectively,
P < 0.01). This suggested that the CPs based on integrative
medicine could decrease the cost of hospitalization through
a reduction in the length of a patient’s in-hospital stay and in
the potential overprescription of drugs and diagnostic tests.
4.3. Health Providers’ Compliance with the Guideline. Despite
strong evidence for the benefits of AMI patient management
using antiplatelet agents, LMWH and lipid-lowering therapies, reports from the CPACS study indicated that physician
compliance with guideline recommendations and sustained
use of medical therapy remains suboptimal [19]. Statins
and LMWH are eﬀective in reducing mortality and serious
coronary events in patients with AMI. Despite the increased
usage rate of these therapies in TCM hospitals, data has
shown a lower prescribing rate in TCM hospitals than in
Western Medicine hospitals [20]. Our results demonstrate
that the use rates of LMWH (100% versus 89%) or statin
lipid-lowering drugs (100% versus 96%) in the intervention
group was higher than in the historical control group, respectively, which revealed that CPs have the potential capacity
to improve health providers’ adherence to published AMI
guidelines and to close the gap between the practice and the

4.4. Management of TCM after Reperfusion Therapy. TCM
plays an important role in the current treatment of AMI
especially in TCM hospitals. In the past 10 years, bloodactivating had emerged as a main TCM method for treating
patients with AMI, thus leading to wide prescribing of
Chinese medicine intravenous preparations that are clinical
blood-activating agents [5]. As a result, there is more usage
of blood-activating intravenous agents in the historical group
(63%), as shown in Table 3. However, in our previous study
that related the distribution and evolvement of syndrome
elements during the perireperfusion period, we found that
reperfusion treatments play a vital role in activating circulation in the TCM theory, and that Qi deficiency and blood
stasis are the main syndromes after reperfusion therapy
[11]. An analysis of 5284 patients with coronary artery
disease indicated that the top two TCM patterns were blood
stasis (79.3%) and Qi deficiency (56.5%) [21]. Therefore,
Qibenefitting and blood activating should become the main
TCM treatment, replacing blood-activating alone. In this
study, Qi-benefitting intravenous agents (e.g., Astragalus,
Shen Mai injection and Shenfu injection) and compound
Danshen dripping pills were used as the standardized TCM
management after reperfusion. Thus, it is reasonable that
the rate of use of these agents in intervention group are
higher than in the historical group (P < 0.01). Other trials
indicated that Astragalus injection was eﬀective in reversing
left ventricular remodeling and improving left ventricular
function in patients with AMI [22], and that Salvia miltiorrhiza extract (the main ingredients of compound Danshen
dripping pills) aﬀords protection against isoproterenolinduced myocardial infarction [23], which demonstrated the
possible mechanism of accelerating cardiac function recovery
using Qi-benefitting and blood-activating compounds. Also,
CPs application based on integrative medicine guarantees an
increase in the standardized usage of TCM therapy (97%
versus 84%).
4.5. Major Adverse Cardiac Events. Despite wide implementation of CPs in cardiovascular disease, no controlled study
has shown that CPs could reduce the incidence of the death
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or MACE in patients with AMI. Our research indicated
that, compared with the historical group, the incidence of
death and MACE during hospitalization was lower in the
intervention group compared to the control group (1.5%
versus 5.4%, 2.5% versus 6.9%, resp., P < 0.05). The reasons
for this encouraging outcome are complex. Multiple factors
including an increase in prescribing drugs, recommended
by AMI guidelines, standardized use of TCM based on
Qi-benefitting and blood-activating, and a decrease in the
variation in care attributed to an improvement in healthcare.

5. Conclusions
Integrative medicine treatment, combining TCM and conventional medicine, has been the most representative characteristic for patients with coronary heart disease in China,
especially those in TCM hospitals. We found that, in the current era of published treatment guidelines, implementation
of the CPs based on the standardized therapies of integrative
medicine could further improve guideline compliance and
overall quality of care by reducing the length of stay and
medical cost for patients with AMI in Chinese hospitals.

6. Limitations of This Study
Although our study revealed the potential improvements in
patient outcome by the development and implementation of
CPs for AMI patients in China, there are several limitations
of the study. First, the duration of the study period was short
because of budget limitations, which leaves uncertainty in the
long-term outcome of patients with AMI. Second, this study
used a nonrandomized retrospective trial design, which may
not fully reflect the improvement of CPs on the quality of
health care due to potential changes in insurance coverage or
policy. Therefore, multicenter large-scale randomized studies
are needed to assess prospectively the diﬀerential eﬀects of
CPs based on integrative medicine versus CPs only based on
western medicine.
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